Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
A bellowing stag and the northern lights : photos of the day – Thursday
30/10/2025
‘Tom Cruise was not happy’ : Colin Farrell was so drunk on Minority Report he needed 46 takes for a single line
30/10/2025
Killer Colin Pitchfork has plea for release from prison rejected
30/10/2025
I Love LA review – Rachel Sennott’s HBO comedy finds itself but takes its time
30/10/2025
Yvonne Brewster obituary
30/10/2025
ECB keeps interest rates on hold despite eurozone inflation fears
30/10/2025